Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

mpany announced that the first study (Study 102) met its primary 48-week efficacy endpoint showing that Viread is non-inferior to Hepsera among patients with HBeAg-negative/anti-HBe positive (presumed pre-core mutant) chronic hepatitis B.

"The preliminary data observed in both Phase III trials evaluating Viread as a potential treatment option for chronic hepatitis B are very encouraging," said Franck Rousseau, MD, Vice President, Clinical Research, Gilead Sciences. "We look forward to reviewing these data with regulatory authorities and are working quickly to file a New Drug Application in the United States and Marketing Authorisation Application in Europe in the fourth quarter of this year."

The active ingredient in Viread, tenofovir DF, is currently the most prescribed molecule in the United States for combination HIV therapy. Viread received approval as an anti-HIV medication from the U.S. Food and Drug Administration (FDA) in October 2001 and from the European Commission in February 2002. Viread is not approved as a treatment for chronic hepatitis B, and data from this analysis have not been reviewed by the FDA.

Study Design

Study 103 is a multi-center, randomized, double-blind Phase III clinical trial that compares the efficacy, safety and tolerability of Viread and Hepsera over 48 weeks among patients with HBeAg-positive chronic hepatitis B. Two hundred and sixty-six patients were randomized in a 2:1 ratio to receive either Viread (300 mg once daily; n=176) or Hepsera (10 mg once daily; n=90).

About Viread (tenofovir disoproxil fumarate)

In the United States, Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Viread should not be used in combination with the fixed-dose combination products Truvada(R) or Atripla(TM) because they already contain Viread.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the u
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014  RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced completion of enrollment in its ... from the 3-month observations confirmed the 1-month findings ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... Md., Nov. 4, 2010 The U.S. Food ... to treat chronic musculoskeletal pain, including discomfort from ... first used to treat major depressive disorder in ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ...
... Calif., Nov. 4, 2010 ThermoGenesis Corp. (Nasdaq: ... and services that process and store adult stem cells, ... China and Hong Kong for its products used to ... at the point-of-care and in the laboratory. ...
Cached Medicine Technology:FDA Clears Cymbalta to Treat Chronic Musculoskeletal Pain 2ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China 2ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China 3ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China 4ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China 5
(Date:12/17/2014)... 17, 2014 This prestigious award ... that have made outstanding and innovative contributions to ... progression of private practice physical therapy by the ... Association. , On behalf of Performance Physical Therapy, ... CEO of Performance accepted the award at the ...
(Date:12/17/2014)... December 17, 2014 No matter how ... able to eradicate the head louse parasite—a common childhood ... parents. Each year between six and twelve million individuals ... Miami-based lice removal treatment company comes to the rescue, ... environmentally friendly. With its track record of customer service, ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... the world of infectious diseases, one worrisome phenomenon is when ... The process -- known as zoonosis -- is not ... for signs that an animal-borne disease might make inroads into ... such a development -- and the culprits in this case ...
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, ... approaching, a new study reveals that states that routinely perform ... drivers on their roads. The finding suggests that states ... to deter inebriated revelers from getting behind the wheel in ... passed regarding drinking and driving," said study lead author James ...
(Date:12/15/2014)... 15, 2014 Cancer researchers have just ... genetic causes of deadly malignant pleural mesothelioma. Surviving Mesothelioma ... their website. Click here to read it now. ... Hawaii Cancer Center, and New York’s Langone Medical Center ... mesothelioma patients in an effort to pinpoint the ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2
... July 7 The American Association of Homes and ... Administration for affirming their commitment to the millions of ... In a letter to the Senate Health, Education, Labor ... Human Services Secretary Kathleen Sebelius expressed the Obama,s administration,s ...
... Institute for Clinical Systems Improvement (ICSI) will hold a symposium ... is dramatically improving patient outcomes and lowering the cost of ... program changes how care for the patient with depression is ... will focus on the 18-month experiences of provider groups, behavioral ...
... relatives reveals clues about course of illness, prognosis, research shows ... history not only reveals their risk for conditions such as ... predict the course of the illness and prognosis, a new ... New Zealand, who were enrolled at age 3 and followed ...
... Comprehensive regulation of gun sellers appears to reduce the ... led by researchers at the Johns Hopkins Bloomberg School ... criminals is important because 85 percent of guns recovered ... not the original purchasers of the guns according to ...
... of early death and disability in Europe, accounting each year ... costing the EU economy an estimated 192 billion. Top level ... to assess current prevention programs and to develop a strategy ... by the European Heart Network and the European Society of ...
... five and a half pounds at birth often enter ... respiratory problems. New research shows that these respiratory problems ... into adulthood. "We report a previously unrecognized ... adults with a history of low birth weight," wrote ...
Cached Medicine News:Health News:Obama Administration Advances Long-Term Services and Supports in Health Care Reform 2Health News:ICSI Plans Symposium on New Depression Treatment Program That Is Improving Patient Outcomes Five-Fold Over Typical Primary Care 2Health News:Family History Key to Psychiatric Disorder Risk 2Health News:Regulation and oversight of gun sales reduces trafficking to criminals 2Health News:Regulation and oversight of gun sales reduces trafficking to criminals 3Health News:Low birth weight linked to long-term respiratory problems 2Health News:Low birth weight linked to long-term respiratory problems 3
... Vest-Skirt Combination gives you the ... Comfort enhanced by distributing 70% ... the hips leaving only 30% ... the shoulders. Freedom of movement ...
One standard,size fits all....
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
... to help lift the weight off your shoulders ... around protection to cover you front, side and ... a breeze. For additional back support try one ... pressure on the vertebrae and help "lift the ...
Medicine Products: